Sildenafil citrate (VIAGRA®): An oral treatment for erectile function with activity for up to four hours' duration

International Journal of Clinical Practice, Supplement

Volumn , Issue 102, 1999, Pages 32-34

  Eardley, I ^a   Brooks, J ^b   Yates, P K ^b   Ellis, P ^b   Boolell, M ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SILDENAFIL; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; ERECTILE DYSFUNCTION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PENIS ERECTION; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; SEXUAL FUNCTION; STIMULATION; DOSE RESPONSE; DRUG EFFECT; IMPOTENCE; MIDDLE AGED;

ADMINISTRATION, ORAL; ADULT; AGED; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PLETHYSMOGRAPHY;

EID: 0032585802     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (1)

1. Boolell M, Allen MJ, Ballards SA et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8(2): 47-52.